Four Women Settle Hair Relaxer Cancer Suits

Four women settled cancer claims against L'Oreal's US subsidiary and other companies during the first hair relaxer trial in Chicago.

Updated on Nov. 16, 2026 in Cancer

Four Women Settle Hair Relaxer Cancer Suits

Live Poll

Do you trust hair straightening products to be safe for regular use?

Four women reached a confidential settlement on Monday with L'Oreal's US subsidiary and other companies over claims they developed gynecologic cancers from years of using chemical hair straighteners. The cases were the first hair relaxer lawsuits to go to trial.

Why it matters

The settlement comes as more than 12,700 similar claims are centralized before a federal judge in Chicago, and as Arizona and Minnesota sue L'Oreal alleging it misled women about the products' safety. L'Oreal has said a 2022 National Institutes of Health study did not establish a causal link between the products and the alleged conditions.

A 2022 National Institutes of Health study found women who used the products several times a year were more than twice as likely to develop uterine cancer, but L'Oreal says it did not establish causation. More than 12,700 claims remain centralized before a federal judge in Chicago, and the settlement sum for the four plaintiffs was not disclosed.

The players

L'Oreal

The French global cosmetics company whose US subsidiary is among the defendants that settled with the four women over hair relaxer products.

The details

The four women alleged they were diagnosed with gynecologic cancers after years of using chemical hair straighteners marketed under names including Dark and Lovely and Optimum. They sued in Cook County, Illinois, in 2023 and 2024, and the trial began November 9 with jury selection before the settlement was reached.

Timeline

  1. 2022: National Institutes of Health study on uterine cancer risk released.

  2. 2023 and 2024: Women file lawsuits in Cook County, Illinois.

  3. November 9, 2026: Trial begins with jury selection in Chicago.

  4. Monday, November 16, 2026: Four women reach settlement during trial.

  5. 2026: Arizona and Minnesota sue L'Oreal over the products.

Legal Context

The lawsuits follow the 2022 National Institutes of Health study linking frequent hair relaxer use to more than double the risk of uterine cancer. The Chicago settlement is the first hair relaxer case to reach trial, as more than 12,700 claims remain consolidated before a federal judge.

Women who regularly use chemical hair straighteners may want to review the 2022 NIH findings with their doctor, since the study linked frequent use to higher uterine cancer risk. The lawsuits are ongoing, and women who used these products may be eligible to pursue claims through the consolidated federal proceedings in Chicago.

The takeaway

Frequent hair relaxer use has been linked in one federal study to a higher risk of uterine cancer, though the manufacturer disputes that the link has been established. Readers who use these products regularly may want to discuss the findings with a healthcare provider.

Further reading

Explore more cancer coverage for context on how these product lawsuits fit into the broader research on cancer risk.

Live Poll

Do you trust hair straightening products to be safe for regular use?